Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Safety and immunogenicity of 15-valent pneumococcal conjugate vaccine compared to 13-valent pneumococcal conjugate vaccine in adults ≥65 years of age previously vaccinated with 23-valent pneumococcal polysaccharide vaccine

Background: Pneumococcal disease remains a public health priority in adults. Previous studies have suggested that administration of pneumococcal polysaccharide vaccine or pneumococcal conjugate vaccine within three years following receipt of PPV23 was associated with increased reactogenicity and red...

Full description

Bibliographic Details
Main Authors: James T. Peterson, Helen L. Stacey, John E. MacNair, Jianing Li, Jonathan S. Hartzel, Tina M. Sterling, Patrice Benner, Gretchen M. Tamms, Luwy K. Musey
Format: Article
Language:English
Published: Taylor & Francis Group 2019-03-01
Series:Human Vaccines & Immunotherapeutics
Subjects:
pneumococcal conjugate vaccine
safety
immunogenicity
Online Access:http://dx.doi.org/10.1080/21645515.2018.1532250

Similar Items

Similar Items